Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 8.01 (Other Events). FDA full clinical hold on ARD-101 investigational new drug application.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA full clinical hold on ARD-101 investigational new drug application
- Clinical development and dosing activities for ARD-101 halted pending FDA resolution
- Material setback for Aardvark’s lead program, potentially delaying timelines and increasing development costs
- Press release details filed as Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.